The juggernaut continues. And the stock is up almost five percent this morning on the NYSE.

Hard to imagine this team ever missing their mark, quarter to quarter. Here’s the latest, from CNBC:

…Merck raked in $18.09 billion in revenue for the quarter, up 5% from the same period a year earlier.

Beyond Keytruda, Merck’s newer products also showed strong growth.

Winrevair, which is used to treat a rare, deadly lung condition, generated $694 million in sales for the quarter, up 93% from the same period a year earlier. Analysts were expecting sales of $645 million.

Meanwhile, the Gardasil vaccine, which prevents cancers from HPV, a very common sexually transmitted infection, drew about $2 billion in sales due to higher demand in the U.S….

Excellent news. Onward.

नमस्ते